Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.41
+0.12 (1.65%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Kyverna Therapeutics Employees
Kyverna Therapeutics had 129 employees as of March 31, 2026. The number of employees increased by 10 or 8.40% compared to the same quarter last year.
Employees
129
Change
10
Growth
8.40%
Revenue / Employee
n/a
Profits / Employee
-$1,212,403
Market Cap
450.49M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 129 | 10 | 8.40% |
| Dec 31, 2025 | 130 | 18 | 16.07% |
| Sep 30, 2025 | 129 | 10 | 8.40% |
| Jun 30, 2025 | 129 | 17 | 15.18% |
| Mar 31, 2025 | 119 | 19 | 19.00% |
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Sep 30, 2024 | 119 | 30 | 33.71% |
| Jun 30, 2024 | 112 | 23 | 25.84% |
| Mar 31, 2024 | 100 | - | - |
| Dec 31, 2023 | 96 | - | - |
| Sep 30, 2023 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| ProKidney | 231 |
| Cabaletta Bio | 158 |
| Ocugen | 116 |
| Cybin | 100 |
| Editas Medicine | 87 |
| Larimar Therapeutics | 71 |
| Prothena Corporation | 67 |
KYTX News
- 4 weeks ago - Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer - TheFly
- 4 weeks ago - Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition - GlobeNewsWire
- 7 weeks ago - Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Kyverna Therapeutics presents updated COMPARE trial data at EULAR - TheFly
- 7 weeks ago - Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis - GlobeNewsWire
- 7 weeks ago - Kyverna Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Kyverna Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts